Test panel for stomach health check
GastroPanel® is a first line diagnostic test for dyspeptic patients. It is a non-invasive blood test, risk free and user friendly laboratory test.
GastroPanel gives information on the structure and function of the stomach mucosa, and of the risks caused by a possible abnormal mucosa. Based on the GastroPanel results, it is possible to get information to support the diagnosis of:
- Healthy stomach mucosa
- Functional and organic dyspepsia (when GastroPanel results indicate a healthy stomach mucosa, the cause of stomach problems is often functional dyspepsia or a disease outside the stomach).
- Atrophic gastritis (damaged stomach mucosa that is severly dysfunctional) and likelihoods of the conditions specifically in the corpus and antrum areas of the stomach (normal, gastritis or atrophic gastritis).
- Helicobacter pylori infection.
- Achlorhydria of the stomach (anacidic stomach).
The test panel consists of four assays:
- Pepsinogen I ELISA
- Pepsinogen II ELISA
- Gastrin-17 ELISA
- Helicobacter pylori IgG ELISA
For more information about the GastroPanel, please visit www.gastropanel.com
Notice – In the USA and Japan, GastroPanel is for research use only. Not for use in diagnostic procedures.
GastroPanel® is a simple laboratory examination performed on a blood sample. It gives diagnosis, for example, of healthy stomach mucosa, Helicobacter pylori (H.pylori) infection and atrophic gastritis. Based on the results, functional dyspepsia can be differentiated from organic dyspepsia. The results also give important information on possible risks related to H.pylori infection, atrophic gastritis and high acid production. GastroPanel examination promotes evidence-based medicine.
H.pylori infection is diagnosed by an antibody test. Pepsinogen I, pepsinogen II and gastrin-17 levels describe the structure and function of the whole gastric mucosa. The more severe is the atrophic gastritis in the corpus mucosa, the lower is the level of pepsinogen I, and the ratio of pepsinogenI/II in blood. The more severe is the atrophic gastritis of antrum mucosa, the lower is the the level of gastrin-17 in blood. For more information on interpretation of the GastroPanel® results, please visit the gastropanel.com web site.
GastroPanel® gives a reliable diagnosis of:
Healthy stomach mucosa. When the stomach mucosa is healthy, the reason for stomach problems is most likely to be functional dyspepsia or disease outside the stomach.
- H.pylori infection.
- Atrophic gastritis (severely damaged and dysfunctional stomach mucosa) and the condition, specifically, of the corpus and antrum mucosa (normal, gastritis or atrophic gastritis)
GastroPanel® is well suited for follow-up of the success of treatment for H.pylori eradication treatment and atrophic gastritis, as well as for their diagnosis. Furthermore, Gastrin-17 level indicates whether the patient may have hyperacidic stomach, and a resulting risk of gastroesophageal reflux disease (GERD) and its complications. GastroPanel can therefore be used to determine whether a patient really needs e.g. commonly described PPI (proton pump inhibitor) medication. If a patient has atrophic gastritis in the corpus, the stomach is hypoacidic, and there is no need for PPIs; if the stomach is hyperacidic, the situation is different.
|Atrophic gastritis diagnosis vs. histology N=404||GastroPanel|
|Positive Predictive Value||75%|
|negative Predictive Value||97%|
Table 1. In a Finnish multicenter study with 404 dyspepsia patients as participants, the performance of GastroPanel was compared to histology. GastroPanel examination diagnosed healthy stomach mucosa nearly as reliably as gastroscopy and biopsy examination. For atrophic gastritis, the accuracy was excellent (81%) compared to histological study (Väänänen et al. Eur J Gastroenterol Hepatol 2003; 15:885-891).
- Zagari et al 2017 | 20 studies, 4241 patients: Systematic review with meta‐analysis: diagnostic performance of the combination of pepsinogen, gastrin‐17 and anti‐Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis
- Syrjänen 2016 | 27 studies, 8654 patients: A Panel of Serum Biomarkers (GastroPanel®) in Non-invasive Diagnosis of Atrophic Gastritis. Systematic Review and Meta-analysis
- Cai et al 2019: Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study
- Syrjänen et al 2019: GastroPanel® Biomarker Assay: The Most Comprehensive Test for Helicobacter pylori Infection and Its Clinical Sequelae. A Critical Review
- Den Hollander et al 2019: Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions
- Tepes et al 2018: Premalignant Gastric Lesions in Patients Included in National Colorectal Cancer Screening
- Tue et al 2017: A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study
- Benberin et al 2013: Prevalence of H. pylori Infection and Atrophic Gastritis Among Symptomatic and Dyspeptic Adults in Kazakhstan. A Hospital-based Screening Study Using a Panel of Serum Biomarkers
- Agreus et al 2012: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers
- Storskrubb et al 2008: Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study
Supported by the international consensus reports:
- Malfertheiner et al 2017: Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report (see page 11)
- Kyoto 2015: Kyoto global consensus report on Helicobacter pylori gastritis (see page 9)
Instructions for use
For the Unified GastroPanel :
For the Standard GastroPanel :